Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 62.2
(0.97%)
EUR 62.2
(0.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 220.25 Million EUR | -13.2% |
| 2022 | 253.73 Million EUR | 39.62% |
| 2021 | 181.73 Million EUR | 134.16% |
| 2020 | 77.61 Million EUR | 84.64% |
| 2019 | 42.03 Million EUR | 164.84% |
| 2018 | 15.87 Million EUR | -7.92% |
| 2017 | 17.23 Million EUR | -58.08% |
| 2016 | 41.11 Million EUR | 97.41% |
| 2015 | 20.82 Million EUR | -23.6% |
| 2014 | 27.26 Million EUR | 19.95% |
| 2013 | 22.72 Million EUR | 11.19% |
| 2012 | 20.44 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 37.18 Million EUR | 94.57% |
| 2024 Q1 | 19.11 Million EUR | -71.15% |
| 2023 Q1 | 60.46 Million EUR | -38.53% |
| 2023 Q2 | 24.57 Million EUR | -59.36% |
| 2023 Q3 | 68.2 Million EUR | 177.58% |
| 2023 Q4 | 66.23 Million EUR | -2.88% |
| 2023 FY | 219.47 Million EUR | -13.5% |
| 2022 Q4 | 98.36 Million EUR | 89.4% |
| 2022 Q3 | 51.93 Million EUR | 46.52% |
| 2022 FY | 253.73 Million EUR | 39.62% |
| 2022 Q2 | 35.44 Million EUR | -48.13% |
| 2022 Q1 | 68.33 Million EUR | 17.33% |
| 2021 Q2 | 30.46 Million EUR | -8.34% |
| 2021 Q4 | 58.24 Million EUR | -2.62% |
| 2021 Q3 | 59.81 Million EUR | 96.34% |
| 2021 Q1 | 33.23 Million EUR | 62.25% |
| 2021 FY | 181.73 Million EUR | 134.16% |
| 2020 Q1 | 14.83 Million EUR | 72.79% |
| 2020 Q4 | 20.48 Million EUR | 4.11% |
| 2020 Q3 | 19.67 Million EUR | -1.25% |
| 2020 FY | 77.61 Million EUR | 84.64% |
| 2020 Q2 | 19.92 Million EUR | 34.29% |
| 2019 FY | 42.03 Million EUR | 164.84% |
| 2019 Q4 | 8.58 Million EUR | -46.57% |
| 2019 Q3 | 16.06 Million EUR | 59.15% |
| 2019 Q2 | 10.09 Million EUR | 38.68% |
| 2019 Q1 | 7.28 Million EUR | 8872.29% |
| 2018 Q4 | -83 Thousand EUR | -101.26% |
| 2018 Q3 | 6.58 Million EUR | 184.87% |
| 2018 Q2 | 2.31 Million EUR | -67.2% |
| 2018 Q1 | 7.05 Million EUR | 428.15% |
| 2018 FY | 15.87 Million EUR | -7.92% |
| 2017 Q3 | -1000.00 EUR | -100.01% |
| 2017 Q1 | 6.99 Million EUR | 552.8% |
| 2017 FY | 17.23 Million EUR | -58.08% |
| 2017 Q4 | -2.14 Million EUR | -214800.0% |
| 2017 Q2 | 10.33 Million EUR | 47.63% |
| 2016 Q2 | 8.44 Million EUR | -17.45% |
| 2016 FY | 41.11 Million EUR | 97.41% |
| 2016 Q4 | 1.07 Million EUR | -64.21% |
| 2016 Q3 | 2.99 Million EUR | -64.53% |
| 2016 Q1 | 10.22 Million EUR | 80.2% |
| 2015 FY | 20.82 Million EUR | -23.6% |
| 2015 Q4 | 5.67 Million EUR | 82.27% |
| 2015 Q3 | 3.11 Million EUR | -56.64% |
| 2015 Q2 | 7.18 Million EUR | 5.14% |
| 2015 Q1 | 6.83 Million EUR | -3.09% |
| 2014 Q4 | 7.04 Million EUR | 36.93% |
| 2014 FY | 27.26 Million EUR | 19.95% |
| 2014 Q1 | 5.94 Million EUR | 76.79% |
| 2014 Q2 | 9.12 Million EUR | 53.69% |
| 2014 Q3 | 5.14 Million EUR | -43.62% |
| 2013 Q2 | 8.82 Million EUR | 55.64% |
| 2013 Q4 | 3.36 Million EUR | -31.18% |
| 2013 FY | 22.72 Million EUR | 11.19% |
| 2013 Q3 | 4.88 Million EUR | -44.65% |
| 2013 Q1 | 5.66 Million EUR | 48.62% |
| 2012 Q4 | 3.81 Million EUR | 0.0% |
| 2012 FY | 20.44 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Boiron SA | 42.29 Million EUR | -420.818% |
| Vetoquinol SA | 74.26 Million EUR | -196.582% |
| Valneva SE | -82.08 Million EUR | 368.318% |
| AB Science S.A. | -13.42 Million EUR | 1740.137% |
| Nanobiotix S.A. | -26.77 Million EUR | 922.488% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 1030.913% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 863.79% |
| BioSenic S.A. | -7.04 Million EUR | 3228.608% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 272.916% |
| Formycon AG | -369 Thousand EUR | 59789.431% |